- Healthcare 150
- Posts
- $100B LatAm Pharma Market + A $950M Diagnostics Bet
$100B LatAm Pharma Market + A $950M Diagnostics Bet
Inside the growth of Latin America’s pharma sector and the big bet on diagnostics.
Good morning, ! This week we’re covering how healthcare M&A strategies are shifting toward smaller, more disciplined deals, the quiet growth of pathology diagnostics powering precision oncology, Agilent’s $950M bet on diagnostic infrastructure, and why Latin America’s pharma market is climbing toward $100B.
Want to advertise in Healthcare 150? Check out our ad platform, here.
Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.
— The Healthcare150 Team
MICROSURVEY
Healthcare M&A Strategy Is Shifting Toward Discipline
Healthcare M&A is still active — but the strategy is becoming far more disciplined.
In our latest Healthcare 150 proprietary microsurvey (N=198), investors and operators signaled a clear shift toward smaller, more targeted deals and deeper operational diligence as financing costs remain elevated and execution risks grow.
The most common strategy change is smaller platform deals paired with add-on acquisitions, cited by 24% of respondents overall and 40% of C-suite leaders, reflecting a more gradual approach to scaling platforms. At the same time, corporate development teams are becoming more selective, with 67% prioritizing tighter sector focus where they have stronger expertise.
Operational scrutiny is also increasing. Half of healthcare M&A specialists highlighted greater pre-close diligence, while investment managers overwhelmingly pointed to deeper operational analysis before closing deals.
The takeaway: healthcare M&A isn’t slowing — it’s becoming more precise, with investors prioritizing specialization, diligence, and operational value creation over aggressive expansion. (More)
HEADLINE OF THE WEEK
Pathology’s Quiet Growth Engine
The market for in situ hybridization (ISH) technologies is expanding steadily, rising from $1.8B in 2025 to $3.6B by 2034, effectively doubling over the decade. Growth is driven by oncology diagnostics, where ISH and related tools such as FISH are increasingly used to detect genetic abnormalities and guide targeted therapies.
The expansion reflects a structural shift in cancer care. Treatment decisions are moving upstream into the pathology lab, where molecular markers determine therapy eligibility. As precision oncology grows, demand for high-specificity tissue diagnostics continues to climb.
Strategically, the opportunity sits in the reagents and assay layers. Antibodies, probes, and companion diagnostic kits carry recurring revenue and high switching costs once embedded in clinical workflows.
Recent deal activity reinforces the trend. Agilent’s $950M acquisition of Biocare Medical highlights how large diagnostics platforms are consolidating specialized assay providers to strengthen their oncology testing capabilities.
Why this matters now: diagnostics infrastructure is becoming a critical gatekeeper for precision medicine. Companies that control the pathology toolkit increasingly control the clinical decision pipeline. (More)
PRESENTED BY JUNIPER SQUARE
New fund formats call for a new operating model: fund operations partner.
Our report on the rise of new fund formats shows a clear shift: operating cadence is increasing, investor workflows are getting more complex, and expectations are moving toward to “always-on.”
That’s why leading PE firms are shifting to a fund operations partner model: one system of record + embedded expertise to run fundraising, investor operations, reporting, and administration with consistent data.
Juniper Square combines purpose-built software + expert fund administration services into a single connected operating model, delivering clearer visibility, fewer failure points, and a modern investor experience.
Read the full breakdown in the report.
Supporting our sponsors supports our free newsletters. Please support our sponsors!
DEAL OF THE WEEK
Agilent Technologies acquires Biocare Medical for $950M
Agilent Technologies is acquiring pathology solutions provider Biocare Medical in a $950M cash transaction, expanding its footprint in clinical diagnostics and oncology testing. The deal brings Biocare’s portfolio of immunohistochemistry (IHC), in situ hybridization (ISH), and FISH technologies into Agilent’s Life Sciences and Diagnostics Markets Group.
The asset base is meaningful. Biocare offers more than 300 specialized antibodies used in pathology labs, with $90M in 2025 revenue and consistent double digit growth under private equity ownership. Agilent’s diagnostics division generated $679M in revenue last quarter, up 5% year over year, giving the company global distribution scale to commercialize these assets more aggressively.
The strategic logic is straightforward. Pathology is becoming the decision layer for oncology, where diagnostic specificity determines therapy selection. Owning the antibody and assay stack strengthens Agilent’s ability to develop in vitro diagnostic tests tied to targeted therapies.
For investors, the signal is consolidation around diagnostic infrastructure. Precision medicine requires deeper pathology capabilities, and large diagnostics platforms are increasingly buying specialized assay developers to secure that layer of the value chain. (More)
REGIONAL FOCUS
LatAm’s Big Four Keep Climbing
Latin America’s pharma growth story is highly concentrated in four countries: Brazil, Mexico, Argentina, and Colombia. Together, they account for about $90B in pharmaceutical sales in 2024, with that figure projected to reach nearly $100B by 2027. The chart tells a clean story: a dip in 2020, followed by a rebound and a steady climb to $99.8B. Each market brings something different. Brazil brings scale. Mexico brings manufacturing and trade access. Argentina brings unusually strong domestic laboratories. Colombia brings the fastest logistics growth of the group. The common thread is that rising demand is pushing more pressure onto the supply chain.
Temperature-controlled distribution, cross-border logistics, and regulatory compliance are no longer support functions. They’re becoming the price of admission. (More)
“The first wealth is health.”
Ralph Waldo Emerson